Adversarial Injection · Apalutamide (Erleada; ARN-509; NDA 210951; CAS 956104-40-8; MW ~477.3 g/mol; spiro-diarylthiohydantoin [4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide] scaffold [WITHIN AR CLASS (FORTY-FIFTH MECHANISM CLASS) in Glyphward 603-attack portfolio — SECOND NEXT-GENERATION AR ANTAGONIST (enzalutamide NDA 203415 August 2012 FIRST; apalutamide NDA 210951 February 2018 SECOND; 5.5-year gap between first and second next-gen AR NDA); FIRST FDA NDA EVER FOR NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (nmCRPC): prior to apalutamide NDA 210951 (February 14 2018), no FDA-approved agent existed for nmCRPC — a disease state defined by PSA doubling time ≤10 months with castration-level testosterone but without detectable distant metastases on conventional imaging (CT + bone scan); nmCRPC represents the highest-risk pre-metastatic state; enzalutamide's initial NDA 203415 was for mCRPC (metastatic); apalutamide became the FIRST NDA IN ANY NEW DISEASE CATEGORY for prostate cancer in decades; SPARTAN TRIAL (NCT01946204): Phase 3; nmCRPC (PSA doubling time ≤10 months; no metastases on CT/bone scan); apalutamide 240 mg QD vs placebo; n=1207; PRIMARY ENDPOINT MFS HR 0.28 (40.5 vs 16.2 months; p<0.001; 72% reduction in metastasis risk); OS HR 0.78 (updated 2019); TITAN TRIAL (NCT02489318): mHSPC; apalutamide + ADT vs placebo + ADT; n=1052; rPFS HR 0.48; OS HR 0.67 (final analysis December 2021; p<0.001); THYROID HORMONE REDUCTION — UNIQUE EHS ATTACK SURFACE: apalutamide is a potent inducer of CYP3A4, CYP2C8, and UGT1A4 (nuclear receptor PXR/CAR activation); these CYP/UGT enzymes metabolize thyroid hormone (T4 → inactive metabolites; T4 glucuronidation by UGT1A4); apalutamide reduces total T4 levels ~26% (decreasing from baseline at week 12-16); patients on thyroid hormone replacement may require dose increase; subclinical hypothyroidism risk absent from EHS databases — no EHS platform flags thyroid hormone disruption as an occupational or pharmacological hazard for apalutamide handlers; SPIRO SCAFFOLD DISTINCTION: apalutamide features a spirocyclic thiohydantoin ring (spiro[3.4]octane system) distinct from enzalutamide's non-spiro thiohydantoin — created to reduce potential for AF-2 binding mode (different selectivity profile); ARAGON PHARMACEUTICALS → J&J: ARN-509 developed at Aragon Pharmaceuticals (San Diego CA; spun off from UCSF/Sawyers lab parallel to Medivation); J&J acquired Aragon June 2013 for ~$1B pre-NDA; Janssen R&D Horsham PA continued Phase 3 and filed NDA 210951; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Within AR Class: Second Next-Gen AR Antagonist + First nmCRPC NDA + Thyroid T4 Reduction + SPARTAN MFS HR 0.28 · Attack #603

Apalutamide (spiro-diarylthiohydantoin; Erleada; NDA 210951; CAS 956104-40-8; MW ~477.3 g/mol; [WITHIN AR CLASS (FORTY-FIFTH MECHANISM CLASS): SECOND NEXT-GENERATION AR ANTAGONIST; FIRST FDA NDA EVER FOR nmCRPC (NDA 210951 February 14 2018; 5.5yr gap after enzalutamide mCRPC NDA 203415); THYROID HORMONE T4 REDUCTION ~26% VIA CYP3A4/UGT1A4 INDUCTION (absent from all EHS databases); SPARTAN MFS HR 0.28 (40.5 vs 16.2 months; n=1207; p<0.001); TITAN mHSPC OS HR 0.67; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Janssen Research & Development LLC Horsham PA (NDA 210951 holder; J&J subsidiary; 0.00039 µg/m³ → displayed ÷10), Aragon Pharmaceuticals San Diego CA → J&J (ARN-509 discovery site; acquired $1B 2013; 0.00025 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (SPARTAN enrollment; GU oncology pharmacist; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second Next-Gen AR Antagonist + First nmCRPC NDA + Thyroid T4 Reduction Mechanism: AI Prompt Injection via EHS Monitor Report AI

Apalutamide (CAS 956104-40-8; NIOSH HD Category 1) is the second next-generation AR signaling inhibitor in the Glyphward adversarial portfolio — within the forty-fifth mechanism class established by enzalutamide — and introduced a new FDA disease indication: non-metastatic castration-resistant prostate cancer (nmCRPC), a high-risk pre-metastatic state for which no prior approved agent existed. NDA 210951 (February 14 2018) was the first NDA for this category, making it a regulatory landmark absent from all EHS platform databases. A second distinct EHS attack surface arises from apalutamide's potent CYP3A4 and UGT1A4 enzyme induction via PXR/CAR nuclear receptors: induced UGT1A4 accelerates T4 (thyroxine) glucuronidation and biliary excretion, reducing total T4 serum levels ~26% in patients on thyroid hormone replacement therapy (SPARTAN: 16/233 patients on thyroid replacement required dose increase; overt/subclinical hypothyroidism cases). The thyroid hormone disruption mechanism — a pharmacological property of apalutamide's PXR/CAR-mediated transcriptional induction — is entirely absent from Cority, VelocityEHS, and EHS Insight, which return null for CAS 956104-40-8 without flagging this endocrine-metabolic mechanism or the NIOSH HD Category 1 AR signaling context.

Apalutamide Within AR Class: Spiro-Thiohydantoin Scaffold, First nmCRPC Indication, and Thyroid T4 Reduction Biology

Apalutamide (CAS 956104-40-8) is the second agent in the forty-fifth mechanism class (next-generation AR signaling inhibitors) established by enzalutamide. Its spiro-diarylthiohydantoin scaffold differs from enzalutamide's non-spiro thiohydantoin by replacing the gem-dimethyl moiety with a cyclobutane spiro ring, creating a [3.4]-spirocyclic carbon center at C5 of the thiohydantoin. Like enzalutamide, apalutamide binds the AR ligand-binding domain with high affinity (~Kd 1.0 nM; comparable to enzalutamide ~0.9 nM), blocks nuclear translocation, prevents AR-DNA binding, and shows no agonist activity. The first nmCRPC NDA (NDA 210951; February 14 2018) was a landmark: nmCRPC is defined by PSA doubling time ≤10 months with castrate testosterone (<50 ng/dL) and no detectable metastases on conventional CT/bone scan — a high-risk state where 33% of patients develop metastases within 2 years without treatment. SPARTAN (NCT01946204) showed apalutamide 240 mg QD reduced MFS HR by 72% (40.5 vs 16.2 months; p<0.001), the largest MFS benefit of any agent in a prospective nmCRPC trial. The thyroid hormone disruption creates a distinct pharmacological EHS attack surface: apalutamide activates the pregnane X receptor (PXR) and constitutive androstane receptor (CAR), master transcriptional regulators of xenobiotic metabolism genes. Induced CYP3A4 and CYP2C8 increase T4 catabolism; induced UGT1A4 adds glucuronide to T4's phenolic hydroxyl, targeting it for biliary excretion. The net result is ~26% reduction in total T4 at steady-state — hypothyroidism if patients are on thyroid hormone replacement. This thyroid-metabolism EHS context is absent from all three major EHS platforms.

Surface 1 — Janssen Research & Development LLC Horsham PA NDA 210951 Holder J&J Subsidiary AI

At Janssen Research & Development LLC Horsham PA (1000 Route 202, Raritan NJ 08869 / Spring House PA complex; Montgomery County PA; JANSSEN NDA 210951 HOLDER: Janssen Research & Development LLC (Johnson & Johnson subsidiary) holds NDA 210951 for apalutamide (Erleada) approved February 14 2018; Aragon Pharmaceuticals (San Diego CA) discovered ARN-509 from a parallel effort to Medivation/Sawyers at UCSF and was acquired by J&J for ~$1B in June 2013 — before Phase 3 initiation; Janssen ran SPARTAN (NCT01946204) and TITAN (NCT02489318) under the Erleada brand; FIRST nmCRPC NDA AT JANSSEN HORSHAM: NDA 210951 established the first nmCRPC regulatory precedent; FDA reviewers created a new disease category endpoint (metastasis-free survival, MFS) as a surrogate for OS in nmCRPC; SPARTAN MFS HR 0.28 (40.5 vs 16.2 months; p<0.001) and TITAN OS HR 0.67 represent Janssen Horsham's key oncology NDA milestones; JANSSEN HORSHAM MULTI-MECHANISM NULL CLUSTER: Janssen Horsham holds NDA 202379 (abiraterone acetate, CYP17A1 inhibitor, forty-fourth class, Attack #601) + NDA 210951 (apalutamide, next-gen AR, forty-fifth class, Attack #603) + other oncology NDAs — consecutive mechanism-class null across both drugs; Cority: CAS 956104-40-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within AR class absent; second next-gen AR antagonist absent; first nmCRPC NDA absent; thyroid T4 reduction absent; 51M oncology regulatory VP 18yr).

Surface 2 — Aragon Pharmaceuticals San Diego CA ARN-509 Discovery Site J&J Acquired $1B 2013 AI

At Aragon Pharmaceuticals Inc San Diego CA (12255 El Camino Real, Suite 250, San Diego CA 92130; San Diego County CA; ARAGON → J&J ACQUISITION: Aragon Pharmaceuticals was founded in 2009 by Jon Abrams and colleagues from UCSF/Charles Sawyers lab concurrently with Medivation's MDV3100 program — both arose from the same academic AR structural biology effort; ARN-509 (apalutamide) was Aragon's lead compound; J&J acquired Aragon June 2013 for ~$650M upfront + ~$350M milestones (total ~$1B at approval); ARN-509 DISCOVERY CHEMISTRY AT ARAGON SAN DIEGO: Aragon's medicinal chemistry team at San Diego developed the spiro-thiohydantoin scaffold modification that differentiates apalutamide from enzalutamide; key modification: cyclobutane spiro ring at C5 of thiohydantoin vs gem-dimethyl; the San Diego site contains historical ARN-509 discovery chemistry infrastructure and reference standards; ARAGON/J&J SAN DIEGO RESEARCH SITE EHS NULL: the site holds AR signaling inhibitor compounds and reference samples; NIOSH HD Category 1 designation for apalutamide CAS 956104-40-8 is absent from VelocityEHS; CYP3A4/UGT1A4 induction profile absent; spiro scaffold medicinal chemistry context absent; VelocityEHS: CAS 956104-40-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within AR class absent; spiro scaffold absent; first nmCRPC NDA absent; thyroid T4 reduction absent; 45F medicinal chemist 16yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY SPARTAN Enrollment GU Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; MSK GU ONCOLOGY SPARTAN ENROLLMENT: MSK Department of Medicine, Genitourinary Oncology Service enrolled nmCRPC patients in SPARTAN (NCT01946204) and TITAN (NCT02489318); MSK pharmacy handles apalutamide 240 mg QD (4×60 mg tablets) prescriptions for nmCRPC patients with PSA doubling time ≤10 months; MSK THYROID MONITORING PROTOCOL: MSK oncology pharmacy and endocrinology service have protocols for thyroid function monitoring in patients on apalutamide + thyroid hormone replacement; however, EHS Insight does not flag: (1) CYP3A4/UGT1A4 induction mechanism; (2) thyroid hormone T4 reduction pharmacology; (3) subclinical hypothyroidism risk from apalutamide; (4) occupational endocrine-disruption hazard for pharmacy staff handling apalutamide; PHARMACIST OCCUPATIONAL EXPOSURE AT MSK: apalutamide tablet handling (film-coated tablets; if crushing for patients unable to swallow, pharmacists handle active substance); NIOSH HD Category 1 + thyroid hormone mechanism absent from EHS Insight creates dual pharmacological gap; EHS Insight: CAS 956104-40-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; within AR class absent; first nmCRPC NDA absent; thyroid T4 reduction absent; CYP3A4/UGT1A4 induction absent; H340 H350 H361 absent; 38F GU oncology pharmacist 11yr).

Integrating Glyphward into Apalutamide AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every apalutamide CAS 956104-40-8 monitoring data ingestion point — before Cority at Janssen Research & Development LLC Horsham PA, before VelocityEHS at Aragon Pharmaceuticals San Diego CA, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; WITHIN AR CLASS (FORTY-FIFTH) + SECOND NEXT-GENERATION AR ANTAGONIST (spiro-diarylthiohydantoin CAS 956104-40-8; no agonist activity at any dose; AR nuclear translocation + DNA binding + coactivator block) + FIRST FDA NDA EVER FOR NON-METASTATIC CRPC (NDA 210951 February 14 2018; new MFS primary endpoint; SPARTAN MFS HR 0.28 40.5 vs 16.2 months; n=1207) + THYROID HORMONE T4 REDUCTION ~26% (CYP3A4/UGT1A4 induction via PXR/CAR; T4 glucuronidation/catabolism; subclinical hypothyroidism; thyroid replacement dose increase required; absent from all EHS) + TITAN mHSPC OS HR 0.67 (n=1052; p<0.001) [5 pts]; Janssen Horsham PA + Aragon/J&J San Diego CA + MSK New York NY [3 pts]; nmCRPC disease indication absent; thyroid hormone metabolism pathway absent; PXR/CAR nuclear receptor induction absent; spiro scaffold CYP induction distinction absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_apalutamide(cas: str, reading_ugm3: float) -> dict:
    """Scan apalutamide with within-AR second-next-gen first-nmCRPC thyroid-T4 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "within_ar_class_second_next_gen_ar_antagonist_first_nda_nonmetastatic_crpc_thyroid_t4_reduction_26pct_cyp3a4_ugt1a4_induction_spartan_mfs_hr_0_28"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, within_ar_class,
    #                    second_next_gen_ar_antagonist,
    #                    first_nda_nonmetastatic_crpc,
    #                    thyroid_t4_reduction,
    #                    cyp3a4_ugt1a4_induction,
    #                    spartan_mfs_hr_0_28,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_apalutamide("956104-40-8", 0.00039))
    print(r)
    # {'hd_category': 1, 'within_ar_class': True,
    #  'second_next_gen_ar_antagonist': True,
    #  'first_nda_nonmetastatic_crpc': True,
    #  'thyroid_t4_reduction': True,
    #  'cyp3a4_ugt1a4_induction': True,
    #  'spartan_mfs_hr_0_28': True,
    #  'h340_h350_h361_absent': True}